Headache News and Research

Latest Headache News and Research

HCV treatment with sofosbuvir and ribavirin results in sustained virologic response

Treatment of chronic hepatitis C virus genotype 1 infection with the interferon-free regimen of sofosbuvir and ribavirin resulted in a high sustained virologic response rate in a patient population with unfavorable treatment characteristics, according to a study in the August 28 issue of JAMA.

28 Aug 2013

FDA approves Galderma's Mirvaso topical gel for facial erythema of rosacea

Galderma Laboratories, L.P. announced that the U.S. Food and Drug Administration has approved Mirvaso (brimonidine) topical gel, 0.33% for the topical treatment of the facial erythema (redness) of rosacea in adults 18 years of age or older. Applied once daily, Mirvaso works quickly to reduce the redness of rosacea and lasts up to 12 hours. Galderma expects Mirvaso to be available in pharmacies September 2013.

27 Aug 2013

Sanofi Pasteur reports clinical benefit of Fluzone High-Dose vaccine in preventing influenza

Sanofi Pasteur, the vaccines division of Sanofi, today announced topline results of a large-scale, multi-center efficacy trial in people 65 years of age and older showing a superior clinical benefit of Fluzone High-Dose (Influenza Virus Vaccine) relative to the standard dose of Fluzone vaccine in preventing influenza.

26 Aug 2013

Takeda announces publication of data from two vedolizumab Phase 3 studies for ulcerative colitis and Crohn’s disease

Takeda Pharmaceutical Company Limited today announced that results from two Phase 3 studies evaluating vedolizumab, an investigational humanized monoclonal antibody, for the treatment of adults with moderately to severely active ulcerative colitis and Crohn’s disease, were published in the August 22, 2013 issue of the New England Journal of Medicine.

22 Aug 2013

Novartis starts shipment of 2013-2014 seasonal influenza vaccines to US customers

Novartis announced today that it has begun shipment of its seasonal influenza vaccines to customers in the US market for the 2013-2014 season. Novartis plans to ship a minimum of 30 million doses of its influenza vaccines to the US market, including Fluvirin (Influenza Virus Vaccine), approved for use in people 4 years of age and older, and Flucelvax (Influenza Virus Vaccine), approved for use in adults 18 years of age and older.

22 Aug 2013

Risk factors linked to death may be reversible in severe encephalitis patients

People with severe encephalitis - inflammation of the brain - are much more likely to die if they develop severe swelling in the brain, intractable seizures or low blood platelet counts, regardless of the cause of their illness, according to new Johns Hopkins research.

21 Aug 2013

Second GSK intramuscular quadrivalent influenza vaccine approved by the FDA

GlaxoSmithKline plc [LSE/NYSE: GSK] announced that the U.S. Food and Drug Administration (FDA) has approved FLULAVAL® QUADRIVALENT (Influenza Virus Vaccine) for the active immunization of persons three years of age and older to help prevent disease caused by seasonal influenza (flu) virus subtypes A and B contained in the vaccine.

19 Aug 2013

Study provides information that validates genetic basis of adaptation to high altitudes

Research led by scientists from the University of California, San Diego has decoded the genetic basis of chronic mountain sickness (CMS) or Monge's disease. Their study provides important information that validates the genetic basis of adaptation to high altitudes, and provides potential targets for CMS treatment.

16 Aug 2013

Scientists uncover potential drug target for effective therapy against bacterial disease brucellosis

UC Davis scientists have uncovered a potential drug target for the development of an effective therapy against the debilitating, chronic form of the bacterial disease brucellosis, which primarily afflicts people in Mediterranean and Middle Eastern countries.

16 Aug 2013

FDA: New drug Tivicay approved to treat HIV-1 infection

The U.S. Food and Drug Administration today approved Tivicay (dolutegravir), a new drug to treat HIV-1 infection. Tivicay is an integrase strand transfer inhibitor that interferes with one of the enzymes necessary for HIV to multiply.

13 Aug 2013

Researchers evaluate accuracy of neurocognitive testing in cheerleaders with concussion

Concussions have become a major public health issue, with both short- and long-term side effects. In sports, cheerleading has the highest rate of catastrophic injury, with some studies reporting approximately 6% of total injuries as concussions. Return-to-play guidelines have relied on athletes' self-reports; however, this has led to concerns about the ability of athletes to truly recognize their own symptoms and recovery.

9 Aug 2013

Lupin acquires exclusive license to promote, distribute Romark's Alinia for Oral Suspension in US

Romark Laboratories announced that it has entered into a strategic agreement with Lupin Limited and its subsidiaries (collectively Lupin) designed to expand promotion and distribution efforts related to its Alinia (nitazoxanide) for Oral Suspension, 100 mg/5 mL. Under the agreement, Lupin acquired an exclusive license to promote and distribute Alinia for Oral Suspension in the United States.

7 Aug 2013

FDA recalls Nova Max Blood Glucose Test Strips due to faulty readings

The U.S. Food and Drug Administration is working with Nova Diabetes Care to recall 21 lots of glucose test strips marketed under the brand names Nova Max Blood Glucose Test Strips and Nova Max Plus Glucose Meter Kits. Nova Diabetes Care announced a recall on July 26, 2013.

1 Aug 2013

GlaxoSmithKline receives CHMP positive opinion for REVOLADE

Ligand Pharmaceuticals Incorporated partner GlaxoSmithKline announced that today, the European Medicines Agency's Committee for Medicinal Products for Human Use issued a positive opinion recommending marketing authorization for GSK's REVOLADE (eltrombopag) as a treatment for low platelet counts (thrombocytopenia) in adult patients with chronic hepatitis C infection, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy

26 Jul 2013

First lots of 2013-2014 seasonal influenza vaccine released for U.S. distribution

Sanofi Pasteur, the vaccines division of Sanofi, announced today that the first lots of Fluzone (Influenza Virus Vaccine) for the 2013-2014 season have been released by the U.S. Food and Drug Administration for U.S. distribution and were shipped July 24.

25 Jul 2013

Study shows good doctor-patient relationships facilitate discussions about health care costs

Strong relationships with physicians, particularly those that are long standing, are likely to increase patients' openness to talk about health care costs when decisions are being made about their treatment options.

24 Jul 2013

Family and friends' fears of recurrence impact on patient's recovery after SAH

Researchers from Durham University and Kings College London (United Kingdom) and the University of Erlangen-N-rnberg (Germany) found that patients who have suffered a subarachnoid hemorrhage (SAH) may not recover psychosocially as well as expected if their significant other is excessively fearful about the possibility of SAH recurrence.

24 Jul 2013

Boston Scientific initiates OPTIMISE trial to study ONS using Precision System for chronic migraine

Boston Scientific Corporation has launched a clinical trial to determine whether occipital nerve stimulation using the Precision System can safely and effectively treat chronic migraine when used in conjunction with anti-migraine medications.

20 Jul 2013

FDA approves Astellas' ASTAGRAF XL for prophylaxis of organ rejection in kidney transplant patients

Astellas Pharma US, Inc., a U.S. subsidiary of Tokyo-based Astellas Pharma Inc., announced today that the U.S. Food and Drug Administration has approved ASTAGRAF XLTM (tacrolimus extended-release capsules) for the prophylaxis of organ rejection in patients receiving a kidney transplant with mycophenolate mofetil and corticosteroids, with or without basiliximab induction.

20 Jul 2013

Teduglutide offers relief for patients with short-bowel syndrome

A new drug, teduglutide, offers significant relief for patients with short-bowel syndrome intestinal failure who are reliant on intravenous nutrition, according to a new study in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association.

19 Jul 2013

Headache News and Research

Latest Headache News and Research

HCV treatment with sofosbuvir and ribavirin results in sustained virologic response

FDA approves Galderma's Mirvaso topical gel for facial erythema of rosacea

Sanofi Pasteur reports clinical benefit of Fluzone High-Dose vaccine in preventing influenza

Takeda announces publication of data from two vedolizumab Phase 3 studies for ulcerative colitis and Crohn’s disease

Novartis starts shipment of 2013-2014 seasonal influenza vaccines to US customers

Risk factors linked to death may be reversible in severe encephalitis patients

Second GSK intramuscular quadrivalent influenza vaccine approved by the FDA

Study provides information that validates genetic basis of adaptation to high altitudes

Scientists uncover potential drug target for effective therapy against bacterial disease brucellosis

FDA: New drug Tivicay approved to treat HIV-1 infection

Researchers evaluate accuracy of neurocognitive testing in cheerleaders with concussion

Lupin acquires exclusive license to promote, distribute Romark's Alinia for Oral Suspension in US

FDA recalls Nova Max Blood Glucose Test Strips due to faulty readings

GlaxoSmithKline receives CHMP positive opinion for REVOLADE

First lots of 2013-2014 seasonal influenza vaccine released for U.S. distribution

Study shows good doctor-patient relationships facilitate discussions about health care costs

Family and friends' fears of recurrence impact on patient's recovery after SAH

Boston Scientific initiates OPTIMISE trial to study ONS using Precision System for chronic migraine

FDA approves Astellas' ASTAGRAF XL for prophylaxis of organ rejection in kidney transplant patients

Teduglutide offers relief for patients with short-bowel syndrome

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Headache News and Research

Latest Headache News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in